Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, colorectal 2

3521 - Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial


10 Oct 2016


Gastrointestinal tumours, colorectal 2


Francois-Clement Bidard


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


F. Bidard1, M. Ychou2, J. Madic3, A. Saliou3, O. Bouché4, M. Rivoire5, F. Ghiringhelli6, E. Francois7, R. Guimbaud8, L. Mineur9, F. Khemissa-Akouz10, T. Mazard2, D. Moussata11, W. Cacheux1, C. Proudhon3, M. Stern12, J. Pierga1, T. Stanbury13, S. Thezenas14, P. Mariani15

Author affiliations

  • 1 Medical Oncology, Institut Curie, 75248 - Paris/FR
  • 2 Department Of Digestive Oncology, Institut Régional du Cancer de Montpellier (ICM), Montpellier/FR
  • 3 Circulating Biomarkers Lab, Institut Curie, Paris/FR
  • 4 Medical Oncology, CHU de Reims - Hôpital Robert Debré, Reims/FR
  • 5 Digestive Oncology, Centre Léon Bérard, Lyon/FR
  • 6 Inserm, U866, Centre Georges-François Leclerc (Dijon), Dijon/FR
  • 7 Service Oncologie, Centre Antoine Lacassagne, Nice/FR
  • 8 Digestive Oncology, CHU Toulouse, Hôpital de Rangueil, Toulouse/FR
  • 9 Radiotherapy And Oncology Gi And Liver, Institut Ste Catherine, Avignon/FR
  • 10 Gastroenterology, CH Perpignan, Hôpital Saint Jean, 66046 - Perpignan/FR
  • 11 Gastroenterology, Centre Hospitalier Lyon Sud, 69310 - Pierre Bénite/FR
  • 12 Inserm U830, Institut Curie, Paris/FR
  • 13 Gi Group, R&D UNICANCER, Paris/FR
  • 14 Biometrics Unit, ICM Regional Cancer Institute of Montpellier, Montpellier/FR
  • 15 Surgical Oncology, Institut Curie, 75248 - Paris/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3521


We prospectively detected circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) levels in patients (pts) included in the PRODIGE14-ACCORD21-METHEP2 randomized phase II trial.


The trial enrolled colorectal cancer pts with potentially resectable liver metastases & no prior treatment; the primary endpoint was the rate of R0/R1 liver metastases resection achieved by 1st line regimen (targeted therapies & bi- vs tri-chemotherapy; Ychou, ASCO 2016). Blood samples were collected at inclusion, after 1 month of therapy and before any liver metastases surgery. CTCs (CellSearch) & ctDNA (ddPCR, BioRad) were detected in an experienced laboratory (Inst. Curie).


153 pts had at least one blood analysis. High CTC count (≥3 CTC/7.5ml) was detected in 25/132 pts (19%) at baseline and associated with synchronous liver metastases (p = 0.03) and % of liver involvement (p = 0.001). At baseline, a 91% sensitivity of KRAS ctDNA detection was observed (42/46 pts with KRAS mutated tumors, as determined per standard of care). In addition, 6 of 79 pts (7%) with tumors considered as KRASwt had >150 KRASmut copies/ml at baseline. After 1 month of therapy, only 3/108 pts (3%) had high CTC count and KRAS ctDNA “sensitivity” dropped to 63% (22/35 pts with KRAS mutated tumors). Among pts planned for liver metastases surgery, none had high CTC count before surgery (0/57) and ctDNA “sensitivity” was 19% (4/21 pts with KRAS mutated tumors). Interestingly, persistently high CTC count (p = 0.06) and detectable KRAS mutated copies (p = 0.002) after 1 month of therapy were significantly associated with a lower R0/R1 liver metastasis resection rate (main study endpoint). Regarding overall survival, CTC count impacted OS at baseline and after 1 month of therapy (p = 0.001), while ctDNA was a prognostic marker only before liver surgery (p = 0.0001).


This is the first study to assess CTC and ctDNA clinical validity in pts with potentially resectable liver metastases. ctDNA detection demonstrated excellent sensitivity at baseline but detection rates dropped during therapy. The major finding is that persistently elevated ctDNA and CTCs after 1 month of therapy may help to select pts that won't undergo later R0/R1 liver metastasis resection.

Clinical trial identification


Legal entity responsible for the study



Merck, Chugai


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings